Replies to post #243344 on Biotech Values

[Biowatch]

What is RVNC time frame for approval/review?

[DewDiligence]

3Q22 worldwide Botox sales=$1.336B, +6% QoQ*, +12% YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-third-quarter-2022-financial-results.htm

• US therapeutic: $584M (+5% QoQ*, +9% YoY)
• US cosmetic: $370M (-18% QoQ*, +4% YoY)
--
US total: $954M (61% therapeutic; 39% cosmetic) was 71% of worldwide total


• Ex-US therapeutic: $115M (-5% QoQ*, +10% YoY†)
• Ex-US cosmetic: $267M (+9% QoQ*, +55% YoY†)
--
Ex-US total: $382M (30% therapeutic; 70% cosmetic) was 29% of worldwide total


*Botulinum-toxin sales are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.

†Ex-US growth measured in local currency.